文档介绍：594
临床与病理杂志
oning 118002, China)
Abstract Objective: To explore the efficacy of colistin sulfate and cefoperazone/sulbactam in the treatment of multidrug-
resistant Acinetobacter baumannii pneumonia. Methods: From March 2019 to July 2021, 76 patients with
multidrug-resistant Acinetobacter baumannii pneumonia were divided into a control group and an observation
group according to the method of random number table. The control group was treated with cefoperazone/
sulbactam 3 g per 6 hours, the observation group was treated with cefoperazone/sulbactam (3 g) and colistin
(1 million units) per day, the treatment course was 14 days. The clinical efficacy and inflammatory factors were
收稿日期 (Date of reception)：2021–11–05
通信作者 (Corresponding author)：史丽珠，Email: ******@***钠舒巴坦钠治疗多重耐药鲍曼不动杆菌的疗效 史丽英，等 591
observed, including the white blood cell count (WBC), serum C-reactive protein (CRP), and procalcitonin (PCT).
Results: Te diference of the efective rates between the 2 groups was statistically signifcant (P<0.